Alzheimer's disease drug development pipeline: 2019
Cleveland Clinic · University of Nevada, Las Vegas · +3 more institutions
Indexed incrossrefdoajpubmed
Abstract
Introduction
Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices.
Methods
We reviewed clinicaltrials.gov and identified all pharmacologic AD trials of all agents currently being developed for treatment of AD.
Citation impact
754
total citations
- FWCI
- 68.80
- Percentile
- 100%
- References
- 49
Citations per year
Authors
5- JLJeffrey L. CummingsCorresponding
Cleveland Clinic, University of Nevada, Las Vegas, Lou Ruvo Brain Institute
- GLGaram Lee
Cleveland Clinic, Lou Ruvo Brain Institute
- ARAaron Ritter
Cleveland Clinic, Lou Ruvo Brain Institute
- MNMarwan N. Sabbagh
Cleveland Clinic, Lou Ruvo Brain Institute
- KZKate Zhong
Nevada State University, Henderson Community College
Topics & keywords
Topics
Keywords
- Drug development
- Clinical trial
- Medicine
- Drug
- Disease
- Phases of clinical research
- Tolerability
- Pharmacology
No related works found for this paper.